K-RAS mutation in the screening, prognosis and treatment of cancer

Biomarkers in Medicine

Volumn 3, Issue 6, 2009, Pages 757-769

  Parsons, Barbara L ^a   Meng, Fanxue ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Biomarker; Carcinogenesis; Mutation detection; Oncogene; Personalized medicine

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE MARKER; DNA SEQUENCE; DRUG MECHANISM; DRUG RESPONSE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MUTANT; MUTATIONAL ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PROGNOSIS; PROTEIN FUNCTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; WILD TYPE;

EID: 75149143640     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.95     Document Type: Review

References (103)

1. Moon A: Differential functions of ras for malignant phenotypic conversion. Arch. Pharm. Res. 29, 113-122 (2006).
2. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160-1174 (2008).
3. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22 (2003). ■ Includes an excellent summary of signaling through EGFR, plus a history of anti-EGFR therapies and a description of their clinical applications.
4. Regina S, Rollin J, Blechet C, Iochmann S, Reverdiau P, Gruel Y: Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J. Thorac. Oncol. 3, 689-697 (2008).
5. Cespedes MV, Sancho FJ, Guerrero S et al.: K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis 27, 2190-2200 (2006).
6. Janssen KP, Abal M, El Marjou F, Loovard D, Robine S: Moose models of K-ras-initiated carcinogenesis. Biochim. Biophys. Acta 1756, 145-154 (2005).
7. Forbes SA, Bhamra G, Bamford S et al.: The catalogue of somatic motations in cancer (COSMIC). Current Protocols in Human Genetics 57 (UNIT 10.11), 11-26 (2008).
8. Lilleberg SL, Durocher J, Sanders C, Walters K, Culver K: High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform. Ann. NY Acad. Sci. 1022, 250-256 (2004).
9. Su YH, Wang M, Aiamkitsumrit B, Brenner DE, Block TM: Detection of a K-ras mutation in urine of patients with colorectal cancer. Cancer Biomark. 1, 177-182 (2005).
10. Diehl F, Schmidt K, Durkee KH et al.: Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 135, 489-498 (2008). ■ Describes a sensitive, quantitative approach for mutant status characterization, with the potential for broad application in clinical sample analysis.
11. Kimura T, Holland WS, Kawaguchi T et al.: Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann. NY Acad. Sci. 1022, 55-60 (2004).
12. Bremnes RM, Sirera R, Camps C: Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 49, 1-12 (2005).
13. Luo JD, Chan EC, Shih CL et al.: Detection of rare mutant K-ras DNA in a single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe. Nucleic Acids Res. 34, E12 (2006).
14. Jiao L, Zhu J, Hassan MM, Evans DB, Abbruzzese JL, Li D: K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: In relation to cigarette smoking. Pancreas 34, 55-62 (2007).
15. Su YH, Wang M, Block TM et al.: Transrenal DNA as a diagnostic tool: Important technical notes. Ann. NY Acad. Sci. 1022, 81-89 (2004).
16. Lichtenstein AV, Melkonyan HS, Tomei LD, Umansky SR: Novel applications of polymerase chain reaction to urinary nucleic acid analysis. Methods Mol. Biol. 336, 145-154 (2006).
17. Su YH, Wang M, Brenner DE et al.: Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J. Mol. Diagn. 6, 101-107 (2004).
18. Destro A, Bianchi P, Alloisio M et al.: K-ras and p16(INK4A) alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer 44, 23-32 (2004).
19. Keohavong P, Gao WM, Zheng KC et al.: Detection of K-ras and p53 motations in sputum samples of lung cancer patients using laser capture microdissection microscope and mutation analysis. Anal. Biochem. 324, 92-99 (2004).
20. Gormally E, Vineis P, Matullo G et al.: TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res. 66, 6871-6876 (2006).
21. Khalid A, Finkelstein S, Mcgrath K: Molecular diagnosis of solid and cystic lesions of the pancreas. Clin. Lab. Med. 25, 101-116 (2005).
22. Loktionov A: Cell exfoliation in the human colon: myth, reality and implications for colorectal cancer screening. Int. J. Cancer 120, 2281-2289 (2007).
23. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med. 351, 2704-2714 (2004).
24. Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE: Noninvasive testing for colorectal cancer: a review. Am. J. Gastroenterol. 100, 1393-1403 (2005).
25. Loktionov A: Common gene polymorphisms, cancer progression and prognosis. Cancer Lett. 208, 1-33 (2004).
26. Rennert G, Kislitsin D, Brenner DE, Rennert HS, Lev Z: Detecting K-ras mutations in stool from fecal occult blood test cards in multiphasic screening for colorectal cancer. Cancer Lett. 253, 258-264 (2007).
27. Whitney D, Skoletsky J, Moore K et al.: Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J. Mol. Diagn. 6, 386-395 (2004).
28. Olson J, Whitney DH, Durkee K, Shuber AP: DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn. Mol. Pathol. 14, 183-191 (2005).
29. Neri M, Cesario A, Granone P et al.: Prognostic role of K-Ras mutations in non-small cell lung cancer: still an issue for open debate. Lung Cancer 53, 393-395; author reply 397-398 (2006).
30. Yamada S, Yashiro M, Maeda K, Nishiguchi Y, Hirakawa K: A novel high-specificity approach for colorectal neoplasia: detection of K-ras2 oncogene mutation in normal mucosa. Int. J. Cancer. 113, 1015-1021 (2005).
31. Parsons BL, Marchant KE, Verkler TL et al.: Quantification of K-RAS codon 12 GAT and GTT mutation in colon tumor and non-tumor tissue by allele-specific competetive blocker PCR. Presented at: The Centennial Annual Meeting of the American Association for Cancer Research. Los Angeles, CA, USA, 14-18 April 2007 (abstract 5245).
32. Magistrelli P, Neri M, Granone P, Cesario A, Paleari L, Russo P: K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value. Pancreas 37, 101-102 (2008).
33. Sawabu N, Watanabe H, Yamaguchi Y, Ohtsubo K, Motoo Y: Serum tumor markers and molecular biological diagnosis in pancreatic cancer. Pancreas 28, 263-267 (2004).
34. Shi C, Fukushima N, Abe T et al.: Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biology Therapy 7, 353-360 (2008).
35. Osborn NK, Ahlquist DA: Stool screening for colorectal cancer: molecular approaches. Gastroenterology 128, 192-206 (2005).
36. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA: Kirsten ras mutations in patients with colorectal cancer: the multicenrer "RASCAL" Study. J. Natl. Cancer Inst. 90, 675-684 (1998).
37. Andreyev HJ, Norman AR, Cunningham D et al.: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br. J. Cancer 85, 692-696 (2001).
38. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA: Assessment of K-ras mutation, a step toward personalized medicine for patients with colorectal cancer. Cancer 115, 3609-3617 (2009).
39. Chang YS, Yeh KT, Chang TJ et al.: Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer 9, 179 (2009).
40. Winder T, Scheithauer W, Lang A: K-ras mutations and cetuximab in colorectal cancer. N. Engl. J. Med. 360, 834-835; author reply 835-836 (2009).
41. Riely GJ, Kris MG, Rosenbaum D et al.: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin. Cancer Res. 14, 5731-5734 (2008).
42. Wang JY, Hsieh JS, Chang MY et al.: Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J. Surg. 28, 721-726 (2004).
43. Trevisiol C, Di Fabio F, Nascimbeni R et al.: Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases. Int. J. Biol. Markers 21, 223-228 (2006).
44. INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Ann. Oncol. 17(Suppl. 7), vii84-vii90 (2006).
45. Frattini M, Gallino G, Signoroni S et al.: Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett. 263, 170-181 (2008).
46. Olsen CC, Schefter TE, Chen H et al.: Results of Phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation. Am. J. Clin. Oncol. 32, 115-121 (2009).
47. Mascaux C, lannino N, Martin B et al.: The rule of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br. J. Cancer 92, 131-139 (2005).
48. Gautschi O, Huegli B, Ziegler A et al.: Origin and prognostic value of circulating KRAS mutatinos in lung cancer patients. Cancer Lett. 254, 265-273 (2007).
49. Camps C, Sirera R, Bremnes R et al.: Is there a prognostic role of K-ras point mutations in the serum of patients with advanced nun-small cell lung cancer? Lung Cancer 50, 339-346 (2005).
50. Neri M, Cesario A, Granone P et al.: Prognostic rule of K-ras mutations in non-small cell lung cancer: still an issue for open debate. Lung Cancer 53, 393-395 (2006).
51. Marchese R, Muleti A, Pasqualetti P et al.: Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas 32, 171-177 (2006).
52. Pao W, Wang TY, Riely GJ et al.: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, E17 (2005).
53. Jackman DM, Yeap BY, Lindeman NI et al.: Phase II clinical trial ufchemutherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J. Clin. Oncol. 25, 760-766 (2007).
54. Schneider CP, Heigener D, Schurt-Von-Romer K et al.: Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study. J. Thoracic Oncol. 3, 1446-1453 (2008).
55. Miller VA, Riely GJ, Zakowski MF et al.: Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J. Clin. Oncol. 26, 1472-1478 (2008).
56. Linardou H, Dahabreh IJ, Kanaloupiti D et al.: Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9, 962-972 (2008).
57. Lievre A, Bachet JB, Le Corre D et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992-3995 (2006). ■■ Important in establishing that K-RAS mutant tumor status could predict failure to respond to therapies directed against the EGFR.
58. Di Fiore F, Blanchard F, Charbonnier F et al.: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br. J. Cancer 96, 1166-1169 (2007).
59. De Roock W, Piessevaux H, De Schutter J et al.: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19, 508-515 (2008).
60. Frattini M, Saletti P, Romagnani E et al.: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 97, 1139-1145 (2007).
61. Khambata-Ford S, Garrett CR, Meropol NJ et al.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230-3237 (2007).
62. Karapetis CS, Khambata-Ford S, Jonker DJ et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
63. Van Cutsem E, Kohne CH, Hitre E et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417 (2009).
64. Freeman DJ, Juan T, Reiner M et al.: Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin. Colorectal Cancer 7, 184-190 (2008).
65. Amado RG, Wolf M, Peeters M et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626-1634 (2008).
66. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al.: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67, 2643-2648 (2007).
67. Staal S, O'connell MJ, Allegra CJ: The marriage of growth factor inhibitors and chemotherapy: bliss or bust? J. Clin. Oncol. 27, 1545-1548 (2009).
68. Chau I, Cunningham D: Treatment in advanced colorectal cancer: what, when and how? Br. J. Cancer 100, 1704-1719 (2009).
69. Allegra CJ, Jessup JM, Somerfield MR et al.: American Society of Clinical Oncology Provisional Clinical Opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096 (2009).
70. Riely GJ, Marks J, Pao W: KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc. 6, 201-205 (2009).
71. Appels NM, Beijnen JH, Schellens JH: Development of farnesyl transferase inhibitors: a review. Oncologist 10, 565-578 (2005).
72. Morgan MA, Ganser A, Reuter CW: Targeting the RAS signaling pathway in malignant hematologic diseases. Curr. Drug Targets 8, 217-235 (2007).
73. Carbone DP, Ciernik IF, Kelley MJ et al.: Immunization with mutant p53- and K-ras-derived peptides in cancer patients: Immune response and clinical outcome. J. Clin. Oncol. 23, 5099-5107 (2005).
74. Brunner TB, Cengel KA, Hahn SM et al.: Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res. 65, 8433-8441 (2005).
75. Duggan BJ, Gray SB, Mcknight JJ, Watson CJ, Johnston SR, Williamson KE: Oligoclonality in bladder cancer: the implication for molecular therapies. J. Urol. 171, 419-425 (2004).
76. Halberg RB, Dove WF: Polyclonal tumors in the mammalian intestine: are interactions among multiple initiated clones necessary for tumor initiation, growth, and progression? Cell Cycle 6, 44-51 (2007).
77. Parsons BL: Many different tumor types have polyclonal tumor origin: evidence and implications. Mutat. Res. 659, 232-247 (2008). ■■ A discussion of how X chromosome inactivation data has heen misinterpreted and a review of evidence supporting polyclonal tumor origin.
78. DieterIe CP, Conzelmann M, Linnemann U, Berger MR: Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-ras mutations in tissue samples of 199 colorectal cancer patients. Clin. Cancer Res. 10, 641-650 (2004). ■■ Establishes that K-RAS mutation is present in colon tumors as subpopulations.
79. Beau-Faller M, Legrain M, Voegeli AC et al.: Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br. J. Cancer 100, 985-992 (2009).
80. Marchetti A, Martella C, Felicioni L et al.: EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23, 857-865 (2005).
81. Mori S, Sugahara K, Uemura A et al.: Rapid, simple, and accurate detection of K-ras mutations from body fluids using real-time PCR and DNA melting curve analysis. Lab. Med. 37, 286-289 (2006).
82. Di Fiore F, Charbonnier F, Lefebure B et al.: Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. Br. J. Cancer 99, 551-552 (2008).
83. Artale S, Sartore-Bianchi A, Veronese SM et al.: Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J. Clin. Oncol. 26, 4217-4219 (2008).
84. Trombino S, Neri M, Puntoni R et al.: Mutations in K-ras codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancer. Clin. Chem. 51, 1313-1314 (2005).
85. Plesec TP, Hunt JL: KRAS mutation testing in colorectal cancer. Adv. Anat. Pathol. 16, 196-203 (2009).
86. Van Krieken JH, Jung A, Kirchner T et al.: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 453, 417-431 (2008).
87. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG: KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J. Clin. Oncol. 27, 1130-1136 (2009).
88. Amur S, Frueh FW, Lesko LJ, Huang S: Integration and use of biomarkers in drug development, regulation and clinic practice: a US regulatory perspective. Biomarkers Med. 2, 305-311 (2008).
89. Su YH, Song J, Wang Z et al.: Removal of high-molecular-weight DNA by carboxylated magnetic beads enhances the detection of mutated K-ras DNA in urine. Ann. NY Acad. Sci. 1137, 82-91 (2008).
90. Mckinzie PB, Parsons BL: Detection of rare K-RAS codon 12 mutations using allele-specific competitive blocker PCR. Mutat. Res. 517(1-2), 209-220 (2002).
91. Diehl F, Schmidt K, Choti MA et al.: Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985-990 (2008).
92. Chen CY, Shiesh SC, Wu SJ: Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: comparison with restriction fragment length polymorphism analysis. Clin. Chem. 50, 481-489 (2004).
93. Luthra R, Medeiros U: Isothermal multiple displacement amplification: a highly reliable approach for generating unlimited high molecular weight genomic DNA from clinical specimens. J. Mol. Diagn. 6, 236-242 (2004).
94. Chen YF, Wang JY, Wu CH, Chen FM, Cheng TL, Lin SR: Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett. 229, 115-122 (2005).
95. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM: Replacing PCR with COLD -PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat. Med. 14, 579-584 (2008).
96. Chen YL, Chang YS, Chang JG, Wu SM: Genotyping of K-ras codons 12 and 13 mutations in colorectal cancer by capillary electrophoresis. J. Chromatography A 1216, 5147-5154 (2009).
97. Zhu D, Xing D, Tang Y, Zhang L: A novel mutant allele specific amplification and electrochemiluminescence method for the detection of point mutation in clinical samples. Biosensors Bioelectronics 24, 3306-3310 (2009).
98. Tol J, Koopman M, Cats A et al.: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563-572 (2009).
99. Bokemeyer C, Bondarenko I, Makhson A et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663-671 (2009).
100. Hecht JR, Mitchell E, Chidiac T et al.: A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27, 672-680 (2009).
101. Catalogue of Somatic Mutations in Cancer. www.sanger.ac.uk/genetics/CGP/ cosmic/ ■ A valuable resource for quick retrieval of pertinent information regarding the propensity for particular tumor types to carry particular tumor-associated mutations, includes data for many different oncogenes and tumor suppressor genes
102. College of American Pathologists Perspectives on Emerging Technology (POET) report. www.cap.org/apps/docs/committees/ technology/KRAS.pdf
103. Draft guidance for industry, clinical laboratories, and FDA staff on in vitro diagnostic multivariate index assays. www.fda.gov/cdrh/oivd/ guidance/1610.pdf